Treat the patient or treat the disease?

Digestive Diseases

Volumn 30, Issue 4, 2012, Pages 400-403

  Hanauer, Stephen B ^a   Kirsner, Joseph B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Crohn's disease; Therapeutic goals; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; C REACTIVE PROTEIN; METHOTREXATE; PREDNISOLONE; PREDNISOLONE 3 SULFOBENZOATE; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID;

ARTICLE; CANCER RISK; CHRONIC DISEASE; COLON MUCOSA; COLON RESECTION; COLONOSCOPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ENDOSCOPY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; LONG TERM CARE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REMISSION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; COLITIS, ULCERATIVE; CROHN DISEASE; ENDOSCOPY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 84863933384     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000338139     Document Type: Article

References (23)

1. D'Haens G, et al: A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-786.
2. Higgins PD, et al: Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol 2005; 100: 355-361.
3. Sandborn WJ, et al: A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122: 512-530.
4. Modigliani R, et al: Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etudes Thrapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1990; 98: 811-818.
5. Landi B, et al: Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Thé rapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992; 102: 1647-1653.
6. Summers RW, et al: National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77(4 Pt 2):847-869.
7. Malchow H, et al: European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-266.
8. Cosnes J, et al: Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-241.
9. Munkholm P, et al: Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-362.
10. Faubion WA Jr., et al: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-260.
11. Froslie KF, et al: Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-422.
12. Colombel JF, et al: Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-1201.
13. Meucci G, et al: Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis 2011, E-pub ahead of print.
14. Rutter M, et al: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-459.
15. Candy S, et al: A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-678.
16. Feagan BG, et al: A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 1627-1632.
17. Markowitz J, et al: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902.
18. D'Haens G, et al: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667.
19. Rutgeerts P, et al: Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-442;quiz 464.
20. Baert F, et al: Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463-468;quiz e10-11.
21. Peyrin-Biroulet L, et al: The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010; 105: 289-297.
22. Vermeire S, van Assche G, Rutgeerts P: Review article: altering the natural history of Crohn's disease -evidence for and against current therapies. Aliment Pharmacol Ther 2007; 25: 3-12.
23. Colombel JF, et al: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395.